Literature DB >> 30296588

Screening for Regulatory Variants in 460 kb Encompassing the CFTR Locus in Cystic Fibrosis Patients.

Jenny L Kerschner1, Sujana Ghosh2, Alekh Paranjapye1, Wilmel R Cosme1, Marie-Pierre Audrézet3, Miyuki Nakakuki4, Hiroshi Ishiguro4, Claude Férec3, Johanna Rommens5, Ann Harris6.   

Abstract

It is estimated that up to 5% of cystic fibrosis transmembrane conductance regulator (CFTR) pathogenic alleles are unidentified. Some of these errors may lie in noncoding regions of the locus and affect gene expression. To identify regulatory element variants in the CFTR locus, SureSelect targeted enrichment of 460 kb encompassing the gene was optimized to deep sequence genomic DNA from 80 CF patients with an unequivocal clinical diagnosis but only one or no CFTR-coding region pathogenic variants. Bioinformatics tools were used to identify sequence variants and predict their impact, which were then assayed in transient reporter gene luciferase assays. The effect of five variants in the CFTR promoter and four in an intestinal enhancer of the gene were assayed in relevant cell lines. The initial analysis of sequence data revealed previously known CF-causing variants, validating the robustness of the SureSelect design, and showed that 85 of 160 CF alleles were undefined. Of a total 1737 variants revealed across the extended 460-kb CFTR locus, 51 map to known CFTR cis-regulatory elements, and many of these are predicted to alter transcription factor occupancy. Four promoter variants and all those in the intestinal enhancer significantly repress reporter gene activity. These data suggest that CFTR regulatory elements may harbor novel CF disease-causing variants that warrant further investigation, both for genetic screening protocols and functional assays.
Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30296588      PMCID: PMC6315324          DOI: 10.1016/j.jmoldx.2018.08.011

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  77 in total

1.  CFTR mutation detection by multiplex heteroduplex (mHET) analysis on MDE gel.

Authors:  Julian Zielenski; Isabel Aznarez; Tuncer Onay; John Tzounzouris; Danuta Markiewicz; Lap-Chee Tsui
Journal:  Methods Mol Med       Date:  2002

2.  First putative sequence alterations in the minimal CFTR promoter region.

Authors:  M C Romey; C Guittard; S Carles; J Demaille; M Claustres; M Ramsay
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

3.  Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms.

Authors:  Claude Férec; Teresa Casals; Nadia Chuzhanova; Milan Macek; Thierry Bienvenu; Andrea Holubova; Caitriona King; Trudi McDevitt; Carlo Castellani; Philip M Farrell; Molly Sheridan; Sarah-Jane Pantaleo; Ourida Loumi; Taieb Messaoud; Harry Cuppens; Francesca Torricelli; Garry R Cutting; Robert Williamson; Maria Jesus Alonso Ramos; Pier Franco Pignatti; Odile Raguénès; David N Cooper; Marie-Pierre Audrézet; Jian-Min Chen
Journal:  Eur J Hum Genet       Date:  2006-05       Impact factor: 4.246

4.  Whole-gene CFTR sequencing combined with digital RT-PCR improves genetic diagnosis of cystic fibrosis.

Authors:  Letizia Straniero; Giulia Soldà; Lucy Costantino; Manuela Seia; Paola Melotti; Carla Colombo; Rosanna Asselta; Stefano Duga
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

5.  From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline.

Authors:  Geraldine A Van der Auwera; Mauricio O Carneiro; Christopher Hartl; Ryan Poplin; Guillermo Del Angel; Ami Levy-Moonshine; Tadeusz Jordan; Khalid Shakir; David Roazen; Joel Thibault; Eric Banks; Kiran V Garimella; David Altshuler; Stacey Gabriel; Mark A DePristo
Journal:  Curr Protoc Bioinformatics       Date:  2013

6.  Evaluation of potential regulatory elements identified as DNase I hypersensitive sites in the CFTR gene.

Authors:  Marios Phylactides; Rebecca Rowntree; Hugh Nuthall; David Ussery; Ann Wheeler; Ann Harris
Journal:  Eur J Biochem       Date:  2002-01

7.  Transcriptional networks driving enhancer function in the CFTR gene.

Authors:  Jenny L Kerschner; Ann Harris
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

8.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

9.  Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms.

Authors:  Marie-Pierre Audrézet; Jian-Min Chen; Odile Raguénès; Nadia Chuzhanova; Karine Giteau; Cédric Le Maréchal; Isabelle Quéré; David N Cooper; Claude Férec
Journal:  Hum Mutat       Date:  2004-04       Impact factor: 4.878

10.  Analysis of long-range interactions in primary human cells identifies cooperative CFTR regulatory elements.

Authors:  Stéphanie Moisan; Soizik Berlivet; Chandran Ka; Gérald Le Gac; Josée Dostie; Claude Férec
Journal:  Nucleic Acids Res       Date:  2015-11-28       Impact factor: 16.971

View more
  3 in total

1.  Comment on: "Multiple acyl‑CoA dehydrogenase deficiency in elderly carriers".

Authors:  Yılmaz Yıldız; Ayşegül Tokatlı
Journal:  J Neurol       Date:  2020-02-12       Impact factor: 4.849

2.  Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity.

Authors:  Alekh Paranjapye; Manon Ruffin; Ann Harris; Harriet Corvol
Journal:  J Cyst Fibros       Date:  2019-11-14       Impact factor: 5.482

Review 3.  Cystic Fibrosis, CFTR, and Colorectal Cancer.

Authors:  Patricia Scott; Kyle Anderson; Mekhla Singhania; Robert Cormier
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.